Brandon Folkes, an analyst from H.C. Wainwright, reiterated the Buy rating on MannKind. The associated price target remains the same with $9.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Folkes has given his Buy rating due to a combination of factors that highlight MannKind’s strategic acquisition and its potential for future growth. The acquisition of scPharmaceuticals Inc. is seen as a positive move, as it diversifies MannKind’s revenue base and allows the company to have more control over its financial future. This strategic decision is expected to enhance the company’s revenue growth by balancing its own marketed products with its partnership revenues.
Additionally, MannKind’s financial flexibility post-acquisition, with a manageable debt level and a significant cash reserve, positions it well for future business development and pipeline expansion. The potential for label expansion of Afrezza and the anticipated approval of SCPH’s FUROSCIX ReadyFlow Autoinjector are seen as significant catalysts that could drive revenue growth. Furthermore, the ongoing internal pipeline and upcoming study results provide additional upside potential, making the acquisition a solid foundation for MannKind’s future value creation.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $11.00 price target.